Aceclofenac:重新评价其使用的疼痛和风湿性疾病的管理。

文章的细节

引用

复制到剪贴板

Dooley M,斯宾塞厘米,邓恩CJ

Aceclofenac:重新评价其使用的疼痛和风湿性疾病的管理。

药。2001;61 (9):1351 - 78。

PubMed ID

11511027 (在PubMed

]

文摘

未标记的:Aceclofenac是一种口服苯乙酸进行导数对各种炎症介质的影响。通过其镇痛和抗炎作用,aceclofenac提供救济的各种症状痛苦的条件。膝骨关节炎患者,药物可以减少疼痛,减少疾病严重程度,改善膝关节的功能能力相似程度双氯芬酸,吡罗昔康和萘普生。Aceclofenac减少关节炎症、疼痛强度和类风湿性关节炎患者晨僵的持续时间,和类似ketoprofen功效,双氯芬酸、吲哚美辛和tenoxicam在这些病人。早上僵硬和疼痛强度的持续时间减少,和脊髓流动性改善,通过在强直性脊柱炎患者aceclofenac,改进是所观察到的类似与吲哚美辛、萘普生或tenoxicam。Aceclofenac也是有效的其他痛苦的条件(例如牙科和妇科)。与其他一些非甾体抗炎药,aceclofenac刺激对软骨基质合成的影响。Aceclofenac耐受性良好,大多数被轻微不良事件和可逆的,和影响主要是胃肠道系统。虽然胃肠道不良事件的发生率与aceclofenac类似个人比较器非甾体类抗炎药的临床试验,退出率由于这些事件与aceclofenac明显低于ketoprofen和tenoxicam。优越的整体和/或胃肠道耐受性药物相对于其他非甾体抗炎药已经被nonrandomised比较表明持续释放10142名患者,双氯芬酸的荟萃分析13比较与双氯芬酸、萘普生、吡罗昔康,吲哚美辛,tenoxicam或ketoprofen 3574名患者,和初步的细节与其他非甾体抗炎药的142776患者。 Further analysis of the above meta-analytical data has indicated that costs incurred as a result of adverse event management are lower with aceclofenac than with a range of comparator NSAIDs. CONCLUSIONS: Trials of 2 to 6 months' duration have shown aceclofenac to be an effective agent in the management of pain and rheumatic disease. Data from in vitro studies indicate properties of particular interest with respect to cartilage matrix effects and selectivity for cyclo-oxygenase-2. Aceclofenac is well tolerated, with encouraging reports of improved general and GI tolerability relative to other NSAIDs from a meta-analysis of double-blind trials and from large nonblind studies.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Aceclofenac